The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.
Andrew H. Ko
Consultant or Advisory Role - Genentech/Roche
Margaret A. Tempero
No relevant relationships to disclose
Tanios B. Bekaii-Saab
Consultant or Advisory Role - Genentech/Roche
Peter Kuhn
Stock Ownership - Epic Sciences
Ryan Courtin
No relevant relationships to disclose
Sharvina Ziyeh
No relevant relationships to disclose
Sanaa Tahiri
No relevant relationships to disclose
Robin Katie Kelley
No relevant relationships to disclose
Elizabeth Dito
No relevant relationships to disclose
Anna Ong
No relevant relationships to disclose
Regina Linetskaya
No relevant relationships to disclose
Olga K. Mirzoeva
No relevant relationships to disclose
Christina Sing-Ying Wu
No relevant relationships to disclose
Alan Paul Venook
Research Funding - Genentech/Roche
Wolfgang Michael Korn
Honoraria - Genentech/Roche